Amarantus Bioscience Holdings Inc. announced that it has formed a wholly-owned subsidiary named Elto Pharma Inc. for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID). Concurrently, the company has formed the wholly-owned subsidiary MANF Therapeutics Inc. for the purpose of the continued pre-clinical development of the internally discovered MANF program in development for the treatment of ophthalmological disorders, including the orphan indications retinitis pigmentosa (RP) and retinal artery occlusion (RAO), in addition to Glaucoma and Parkinson's disease. The company's PhenoGuard protein discovery engine that led to MANF's discovery will also be an asset of MANF Therapeutics.